SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Eikon Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

282564103

(CUSIP Number)

02/04/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

282564103

Names of Reporting Persons

Abu Dhabi Investment Authority

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED ARAB EMIRATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,669,576.00
6	Shared Voting Power 1,147,138.00
7	Sole Dispositive Power 1,669,576.00
8	Shared Dispositive Power 1,147,138.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,816,714.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.2 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: (1) Abu Dhabi Investment Authority is the direct owner of 1,669,576 of the shares of Common Stock represented herein. (2) The percent calculation is based on 53,984,337 shares of Common Stock outstanding, after giving effect to the completion of the offering as described in Eikon Therapeutics, Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 5, 2026.

SCHEDULE 13G

CUSIP No.

282564103

Names of Reporting Persons

Platinum Falcon B 2018 RSC Limited

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED ARAB EMIRATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,147,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,147,138.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,147,138.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

2.1 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the Securities and Exchange Commission, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation based on 53,984,337 shares of Common Stock outstanding after giving effect to the completion of the offering as described in Eikon Therapeutics, Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 5, 2026.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Eikon Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

230 Harriet Tubman Way, Millbrae CA 94030

Item 2.

(a)

Name of person filing:

This Schedule 13G is being filed on behalf of the following: 1. Abu Dhabi Investment Authority 2. Platinum Falcon B 2018 RSC Limited

(b)

Address or principal business office or, if none, residence:

The principal business address of each of the Reporting Persons is as follows: 1. 211 Corniche Street P.O. Box 3600 Abu Dhabi, United Arab Emirates 3600 2. Level 26, Al Khatem Tower Abu Dhabi Global Market Square Al Maryah Island, Abu Dhabi United Arab Emirates

(c)

Citizenship:

1. Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. ADIA is a public institution. 2. Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.

(d)

Title of class of securities:

Common Stock, par value $0.0001 per share

(e)

CUSIP No.:

282564103

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

See responses to Item 9 on each cover page.

(b)

Percent of class:

See responses to Item 11 on each cover page.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

(ii) Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Abu Dhabi Investment Authority

Signature:	/s/ Saif Surour Omair Maaded AlMashghouni
Name/Title:	Authorized Signatory
Date:	02/18/2026

Signature:	/s/ Ahmed Salem Abdulla Melaih AlNeyadi
Name/Title:	Authorized Signatory
Date:	02/18/2026

Platinum Falcon B 2018 RSC Limited

Signature:	/s/ Saif Surour Omair Maaded AlMashghouni
Name/Title:	Authorized Signatory
Date:	02/18/2026

Signature:	/s/ Ahmed Salem Abdulla Melaih AlNeyadi
Name/Title:	Authorized Signatory
Date:	02/18/2026

Exhibit Information

Exhibit 1: Joint Filing Agreement

SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.